[Fondaparinux: the present and the future].
The development of new antithrombotic molecules which induced an inhibition of activated factor X (fondaparinux, Arixtra) shows effectiveness and safety in prevention of thromboembolic disease in surgery, but also in the treatment of the pulmonary embolism and major venous thromboses and acute myocardial infarction. Recent clinical trials show that new anti-Xa inhibitors also have interesting properties in antithrombotic therapy. Fondaparinux could offer new therapeutic possibilities that could simplify the management of patients under anticoagulant treatment.
Garcia Hejl
C
C
Laboratoire de biochimie, HIA Val-de-Grâce, 74, boulevard Port-Royal, 75005 Paris, France. carinegarcia92@wanadoo.fr
Garcia
C
C
Thefenne-Astier
H
H
Servonnet
A
A
Samson
T
T
Foissaud
V
V
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D001777:Blood Coagulation; D003546:Cysteine Endopeptidases; D004347:Drug Interactions; D000077425:Fondaparinux; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D011134:Polysaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D009363:Neoplasm Proteins; D011134:Polysaccharides; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant; D000077425:Fondaparinux